Viewmind

The eye is the window to the brain

ViewMind uses ocular digital phenotyping, through the use of a Head Mounted Display (HMD) device and statistical models to evaluate brain health, providing precise measurements of various cognitive domains and their associated brain regions. 

Scientific partnerships:

ViewMind difference

Precision Advantage

ViewMind’s patented technology is based on fundamental scientific research performed over 20 years under the leadership
of ViewMind’s Chief Science Officer, Gerardo Fernandez PhD

Dr. Fernandez conducted research at some of the world’s leading institutions, including in Argentina, the United Kingdom, the United States, and Germany.

 

ViewMind technology and proprietary tests shows remarkable accuracy as evidenced in 79 peer-reviewed publications with over 3,000 citations. It has been studied in thousands of patients across four continents in clinical trials, including a 4-year longitudinal study and a study in a familial population with Alzheimer’s disease. 

Published studies:

Clinical studies
conducted or in progress:

Publications

Vector

Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer’s disease

Mario Parra, Juan Granada, Gerardo Fernandez

 

Alzheimers Dement (Amst), 2022

Vector

The eye as a biomarker for Alzheimer's disease: oculomotor behaviours yield a novel digital biomarker for preclinical risk detection

Fernandez, Gerardo and Mendez, Luis and Lopera, Francisco and Fernandez, Gerardo and Mendez, Luis and Lopera, Francisco and Parra Rodriguez, Mario

Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 2022
Vector

Oculomotor abnormalities in offspring of late-onset Alzheimer’s disease

Fernandez G, Gonzalez AP, Abulafia C, Fiorentini L, Agamennoni O, Guinjoan S.

Current Alzheimer Research, 2022
Vector

Oculomotor Behaviors and Integrative Memory Functions in the Alzheimer’s Clinical Syndrome

Fernandez Gerardo & Parra Mario

Journal of Alzheimer’s disease, 2021

How it works

ViewMind gathers and analyzes eye movement patterns to generate precise outcomes driven by advanced technology

Traditional neuropsychological assessment tests are primarily concerned with behavioral response. Is the provided answer correct or incorrect? The majority of the cognitive decision-making signal is disregarded.

 

ViewMind’s technology analyzes every cognitive processing step based on eye-movement responses to visual stimuli. The signal fidelity is over a million times greater than traditional assessments.

 

ViewMind measures eye-movement responses to visual stimuli using a Head Mounted Display (HMD) device, which is more accurate compared to separate camera sensors, and which provides a highly controlled environment. Eye movement patterns change precisely and repeatedly based on alterations in cognition, like fingerprints, so having the most sensitive instrument for these measurements is key.

Group 10760

Head Mounted Display

Head Mounted Display enables ViewMind to conduct an analysis of eye movement in a controlled environment, using high-fidelity equipment for the most accurate results.

Group 10761

Eye movement assessment

ViewMind tracks reproducible phenotypic eye movement patterns to reveal the state of cognitive domains and related brain regions.
Group 10762

AI-based analysis

ViewMind’s patented software identifies minor deviations in oculomotor patterns, quantifies them, and correlates them with the eye patterns of specific pathologies and neurocognitive functions.

ViewMind Industry Applications

Pharmaceutical companies

Pre-screen prospective study participants with a scalable, non-invasive solution. Cognitively match cohorts. Measure the impact of new drugs on cognitive health.

Healthcare institutions

Assess and monitor patients’ brain health. Measure the impact of treatments on their neurocognitive resources.